Dear Editor,

In December, 2019, a series of pneumonia cases of unknown cause emerged in Wuhan, Hubei, China \[[@CR1]\] and further a novel coronavirus was isolated from lower respiratory tract samples, which was further named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) \[[@CR2]\]. The SARS-CoV-2 disease was officially given the name of Corona Virus Disease 2019 (COVID-19) on 11 February, 2020. In this study, we examine which treatments are being used, assess clinical and laboratory features and short-term outcomes of patients with COVID-19 in intensive care unit (ICU).

This retrospective case series involved 102 adult patients with COVID-19 admitted to Wuhan University Zhongnan Hospital in Wuhan, China, between January 3 and February 1, 2020. All those patients received a laboratory-confirmed SARS-CoV-2 infection diagnosis \[[@CR3]\]. Epidemiological, clinical, radiological characteristics, underlying diseases, laboratory tests at admission and during hospitalization, treatment, complications and outcomes data were collected \[[@CR3], [@CR4]\]. Patients outcomes (discharge or death) and admission to ICU (yes or no) were followed up at discharge until February 15, 2020. The study was approved by Zhongnan Hospital Ethics Committee, and oral consent was obtained from patients or relatives.

Demographic details of the included 102 patients are shown in the supplementary table 1. All patients were isolated. Seventeen patients died (discharge mortality, 16.7%; 95% confidence interval \[CI\], 9.4--23.9%), and eighteen patients were admitted to the ICU with a rate of 17.6% (95% CI, 10.2--25.0%). The reasons for admission included need for mechanical ventilation (*N* = 6), breathing rate increases/oxygen saturation \< 90%/no-compliance with noninvasive ventilator (*N* = 7), and combined shock and/or organ failure (*N* = 5). The timeline of SARS-CoV-2 onset in ICU patients is shown in Fig. [1](#Fig1){ref-type="fig"}. The ICU patients were older (66\[54--76\] vs. 31\[35--62\]) and more likely exposed to source of transmission (66.7% vs. 40.2%) when compared to the non-ICU patients. Health care workers were less likely admitted to the ICU (0% vs. 28.2%). ICU patients more likely suffered from comorbidities (Any \[100.0% vs. 34.5%\]; hypertension \[55.5% vs. 21.4%\]; and chronic liver disease \[11.1% vs. 0%\]). Those patents needed more time to confirm the laboratory diagnosis (12\[7-19\] vs. 8\[4-11\]). They also needed longer hospital stays (15\[8--21\] vs. 10\[7--14\]) and more medical expenses (62,556\[48,938--160,629\] vs. 12,808\[8166--27,691\] CNY, See the supplementary table 1).Fig. 1The timeline of SARS-CoV-2 onset in ICU patients. **a** Timeline of SARS-CoV-2 onset in ICU survivors (*N* = 12). **b** Timeline of SARS-CoV-2 onset in ICU non- survivors (*N* = 6). The results were presented as number (%). The onset of symptom was defined as day 0. The points represent the median value. ICU, intensive care unit; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; MV, mechanical ventilation; NV, noninvasive ventilation; IMV, invasive mechanical ventilation; EMCO, extracorporeal membrane oxygenation; OI, oxygen inhalation; ACI, acute cardiac injury; AKI, acute kidney injury; ALI, acute liver injury

As shown in the supplementary table 1, the treatment in ICU included the administration of a antiviral therapy (100.0%), the use of antibiotics (100.0%), glucocorticoid therapy (61.1%), oxygen inhalation (61.1%), noninvasive ventilation (11.1%), invasive mechanical ventilation (38.9%), extracorporeal membrane oxygenation (16.7%) and CRRT (22.2%). Furthermore, there were no significant difference in drugs treatment, oxygen inhalation and noninvasive ventilation between ICU group and non-ICU group (*P* \> 0.05 all). ICU patients received more intensive treatment with invasive mechanical ventilation (38.9% vs. 4.8%), extracorporeal membrane oxygenation (16.7% vs. 0%) and CRRT (22.2% vs. 2.4%). They also more likely suffered from in-hospital complications (ARDS \[44.4% vs. 14.3%\]; acute infection \[38.9% vs. 11.9%\]; acute cardiac injury \[33.3% vs. 10.7%\]; arrhythmia \[38.9% vs. 13.1%\]; acute kidney injury \[44.4% vs. 14.3%\] and acute liver injury \[66.7% vs. 26.2%\]). ICU patients had a higher mortality rate than non-ICU patients (33.3% vs. 13.1%), but this difference was not significant (*P* = 0.081).

Our results suggest that ICU patients suffer at admission from more comorbidities and develop many complications due to hospitalization. During hospitalization they receive more aggressive treatment, and can result in a similar mortality when compared to non-ICU patients. We found that 17.6% of patients required admission to the ICU and 16.7% died. A previous study including 138 patients with COVID-19 showed that 26% of patients required admission to the ICU and 4.3% died \[[@CR3]\]. Another study reported that 23% of patients with COVID-19 required admission to the ICU and 11.0% died \[[@CR4]\]. It should be noted that most patients in those two studies were still hospitalized at the time of manuscript submission \[[@CR3], [@CR4]\]. Our hospital is one of the major tertiary teaching hospitals and is responsible for the treatment of critically ill patients with COVID-19. Thus, our cohort might represent the more severe COVID-19 patients and the rates of death and ICU admission may be overestimated. A recent large-sample and multicenter study showed that only 5% of the included COVID-19 patients were admitted to ICU and 1.36% succumbed \[[@CR5]\].
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